Tirzepatide Cost: Prices, Coverage, and the Vial Option

List price and what people actually pay

Without coverage or discounts, brand-name tirzepatide runs roughly 1,000 to 1,300 dollars per 28-day supply at list price, with Zepbound (weight management) and Mounjaro (diabetes) in a similar range. Almost no one pays exactly the sticker, because savings cards, insurance, and a manufacturer cash program sit between list price and your out-of-pocket. Every figure here is a range that moves by pharmacy, plan, and month.

Brand vs generic

There is no generic tirzepatide. It is a newer molecule fully under patent, so anything sold as generic or research-grade tirzepatide is a compounded or unapproved product, not an FDA-approved generic. If lower cost is the priority, an older option such as generic liraglutide is a legitimate cheaper alternative, though it produces less weight loss and is a daily shot.

Insurance and prior authorization

Coverage is the biggest swing factor. Plans cover the diabetes brand (Mounjaro) more readily than the weight brand (Zepbound), and many commercial plans exclude anti-obesity drugs. Expect a prior authorization where coverage exists: documentation of BMI, weight-related conditions, and sometimes prior treatment attempts. For the sleep-apnea indication of Zepbound, a documented diagnosis may open coverage paths that pure weight-loss claims do not.

The single-dose vial option

The manufacturer has offered lower-priced single-dose vials of tirzepatide through a direct cash program, priced below the autoinjector pens. These require drawing the dose with a syringe rather than using a pen, which suits men comfortable with a simple injection technique and looking to lower cost. Availability and pricing of specific vial strengths change, so confirm current terms directly.

Savings and assistance

Eli Lilly offers savings cards that can substantially lower the copay for commercially insured patients, with amounts and eligibility that change over time and exclude government-insured patients. A patient-assistance program exists for those who are uninsured and meet income criteria. As with any manufacturer program, verify the current terms rather than relying on a figure you saw months ago.

Route to obtain	Typical monthly out-of-pocket	What drives the number
Brand pen, no coverage	~$1,000 to $1,300	Full list price
Manufacturer single-dose vials	Below pen list price	Direct cash program, terms change
Brand with savings card	~$0 to a few hundred	Commercial insurance plus card
Covered with prior auth	Plan copay or coinsurance	Insurer tier and documentation
Compounded tirzepatide	~$200 to $500	Not FDA-approved; quality unverified
Telehealth subscription	Fee plus drug cost	Visit and follow-up bundled or added

Compounded tirzepatide: cheaper and riskier

Compounded tirzepatide typically runs 200 to 500 dollars a month and spread during branded shortages. It is not FDA-approved, is not reviewed for potency, purity, or manufacturing quality, and the FDA has warned about the risks of compounded GLP-1-class products, including dosing errors and untested formulations. As branded supply recovered, the legal room for mass compounding narrowed. The low price is real, and so is the reduced oversight. If a program offers strikingly cheap injectable tirzepatide, ask what form it is, where it is made, and who is accountable.

Telehealth pricing: read the fine print

Online programs quote a monthly number whose meaning varies. Some bundle the medication, the provider visit, and follow-up into one price. Others charge a membership on top of separately purchased medication. A few advertise a low figure that only covers a consultation. Because tirzepatide has more dose steps than semaglutide, ask specifically what happens to your price as the dose climbs, whether the drug is branded pen, manufacturer vial, or compounded, and what you owe if you pause or cancel. OmenRx does not prescribe, sell, or dispense; we explain the pricing so you can judge a program's numbers.

How the dose ladder affects your bill

Tirzepatide is titrated through several strengths, and pricing is not always flat across them. Some pharmacies and programs charge by strength, so your monthly cost can rise as you move up from the starting dose toward maintenance. The single-dose vial program has offered different prices for different strengths, which means the cheapest month at the bottom of the ladder is not what you will pay at a higher maintenance dose. When you compare programs, compare the price at the dose you are likely to settle on, not the introductory strength, or you will underestimate the real cost.

Hidden costs to budget for

The medication is not the only line item. Plan for baseline and follow-up labs, which may carry a copay or a cash charge if you are uninsured. Budget for consultation and follow-up visit fees, which some telehealth programs bill separately from the drug. If you use vials rather than pens, you will need syringes and alcohol swabs, cheap but not free. Because this is long-term treatment, think in annual terms: even a mid-range monthly figure adds up to several thousand dollars a year, and that is the number worth planning around.

Questions to ask before paying

• Is this price for FDA-approved branded tirzepatide (pen or manufacturer vial), or a compounded product?
• What will I pay at my likely maintenance dose, not just the starting dose?
• Are labs, the consultation, and follow-up included or billed on top?
• What is the cancellation policy, and is there a minimum commitment?
• If my insurance approves coverage later, can I switch without penalty?